Home/Omeros Corporation/Michael K. Shetzline

MK

Michael K. Shetzline

Chief Medical Officer and Head of Development

Omeros Corporation

Therapeutic Areas

Immunology Nephrology Hematology Ophthalmology Central Nervous System

Omeros Corporation Pipeline

Drug	Indication	Phase
Narsoplimab (OMS721)	HSCT-Associated Thrombotic Microangiopathy (HSCT-TMA)	BLA Submitted
OMS906	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1
OMS527	Addiction / Substance Use Disorders	Phase 1

Leadership Team at Omeros Corporation

Gregory A. Demopulos

Chairman and Chief Executive Officer

Michael A. Jacobsen

Chief Financial Officer

Michael L. Rupp

Chief Commercial Officer

Michael D. E. Bowen

Chief Business Officer

View full Omeros Corporation profile